EATRIS is delighted at the recent news that Amsterdam won the bid for the European Medicines Agency (EMA), following their decision to leave their current London-based location.
The much-anticipated move brings the EMA closer to EATRIS headquarters at a time when focus in on continuing to foster positive and productive interaction between academia and regulators.
The EMA, charged with evaluating human and animal medicinal products for the European Union, is set to relocate to Amsterdam by 2019, after the city was selected in a draw over Milan. It employs over nine hundred people and hosts thousands of visitors, for hundreds of meetings, every year.
Giovanni Migliaccio, EATRIS’ Scientific Director and former member of the Committee for Advanced Therapies (CAT) of the EMA, said ‘This is an exciting moment for us at EATRIS, that is perfectly timed with the EMA’s new framework for collaboration with academia. We hope it will help us to fulfil our goals of assisting in developing the European regulatory science agenda and supporting academia by providing regulatory expertise.’
Academia, a major driving force in the development of safe and effective medicinal product, and regulators are seeking more interaction to support the translation of innovation. Recently, a framework for collaboration between both worlds was published by EMA.
Anton Ussi, Operations & Finance Director, added ‘EATRIS is all about science meeting regulations and now that EMA will be just a stone’s throw from EATRIS headquarters we will be able to continue to cultivate this interaction easily.’
For further information contact Katherine Blom, Communications Manager: